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Background: The use of isosulfan blue dye in sentinel node biopsy for breast cancer has
been questioned because of its risk of allergic reaction. We hypothesized that blue dye could be
safely omitted in the subgroup of patients who have evidence of successful sentinel node
localization by lymphoscintigraphy.
Methods: A retrospective review of patients with breast cancer and sentinel node biopsy
was conducted. Information was collected on lymphoscintigraphy results, use of blue dye, and
intraoperative and pathologic findings of sentinel nodes.
Results: We identified 475 patients with breast cancer who underwent 478 sentinel node
biopsies. Both dye and isotope were given in 418 cases, of which 380 had a positive lym-
phoscintigram. In 5 of the 380 cases with a positive lymphoscintigram, the sentinel nodes
obtained were blue but not hot, for a 1.3% marginal benefit of dye in the technical success of
the procedure. Sentinel nodes positive for metastasis were found in 102 of 380 cases; in 3 cases,
the only positive sentinel node was blue but not hot. Omission of the blue dye tracer would
have increased the false-negative rate of the sentinel node procedure by approximately 2.5%.
Conclusions: Even in sentinel node biopsy cases with a positive lymphoscintigram, the use
of blue dye is beneficial for both improving the technical success of the procedure and reducing
the false-negative rate of the procedure. Because the marginal benefits of dye justify its routine
use, strategies to minimize the toxicity of blue dye are warranted.
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Sentinel lymph node biopsy (SLNB) in breast
cancer has rapidly evolved as the preferred procedure
for staging the axilla. Multiple techniques seem to be
successful according to published reports.1–5 The
primary variations in technique surround the use of
single versus dual mapping agents, the location of the
tracer injection, and the use of lymphoscintigraphy.
Although methylene blue has been reported for
lymphatic mapping in two series of breast cancer
patients,6,7 the most commonly used blue dye tracer
in the United States is isosulfan blue dye.
Isosulfan blue dye carries a small but significant
risk of allergic reaction, including possible anaphy-
laxis.8 One logical approach to reduce allergic reac-
tions to isosulfan blue dye is to use the dye selectively,
i.e., only in cases in which isotope mapping fails.
Therefore, we investigated whether the dye provides
any marginal benefit in patients with a positive lym-
phoscintigram. In this subgroup with successful iso-
tope localization to the axilla, the risk of allergic
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reaction might be avoided without compromising the
success of the procedure.
METHODS
A retrospective, institutional review board–ap-
proved chart review was performed on breast cancer
patients who underwent SLNB at the University of
Michigan from October 1997 to November 2002.
Information was collected on isotope and lympho-
scintigraphy findings, use of blue dye, and sentinel
node findings. Due to evolution of technique over
time, lymphatic mapping was performed with varying
methods: either 99mTc 3–4 mCi, isosulfan blue dye, or
both. Peritumoral injections were performed by
injection of tracer at four sites surrounding the pal-
pable or estimated site of the lesion. For peritumoral
dye injections, a 4-mL volume was used. Intradermal
injection of radioisotope or dye (.5 mL) was per-
formed directly overlying a palpable lesion, at the
areolar edge if the lesion was nonpalpable, or ceph-
alad to a prior biopsy scar if one was present. Lymph
nodes with evidence of blue dye uptake or radioac-
tivity as detected with an intraoperative gamma
probe (Navigator; US Surgical, Norwalk, CT) were
labeled as sentinel nodes. Lymph nodes that were
palpably suspicious during surgery were also labeled
as sentinel nodes. The sentinel lymph nodes were
processed by following current recommendations.9,10
Briefly, each sentinel node was measured and entirely
cut along its longitudinal axis into sections 1.5 to 2
mm thick. The sections were submitted in formalin
for paraffin section histology, and each paraffin block
was sectioned at three levels. Immunohistochemical
staining for cytokeratin was performed routinely
from July 1999 to June 2001. After that time, cyto-
keratin staining was performed only for clarification
of indeterminate findings on hematoxylin and eosin
stain.
Harvested sentinel nodes were individually char-
acterized as hot only, blue only, both, or palpably
suspicious. Pathologic evaluation of the sentinel
nodes was classified as positive, negative, or cyto-
keratin-only positive. Data were analyzed regarding
the method of tracer injection and the contribution of
blue dye to the technical success of lymphatic map-
ping and its false-negative rate.
RESULTS
We identified 475 patients (including 4 men) with
breast cancer who underwent 478 sentinel node
biopsies. Histology included 333 cases (70%) of
invasive ductal carcinoma, 47 (10%) invasive lobular
carcinomas, 34 (7%) ductal carcinomas-in-situ, 25
(5%) ductal carcinomas-in-situ with microinvasion,
and other histological findings in 39 cases (8%;
Table 1). There were 473 successful SLNB proce-
dures, with a mean of 2.37 nodes harvested according
to the surgeon and a mean of 2.95 nodes identified by
pathologic analysis. A positive sentinel node was
found in 135 patients, of which 117 underwent com-
pletion axillary node dissection. Of the 478 cases,
there were 5 (1.0%) with technical failure of the SLNB
procedure. Two of these patients underwent lympha-
tic mapping with dye alone. Of the other three tech-
TABLE 1. Characteristics of surgical procedures and tumor histology




Successful SLNB procedures 473
SNs harvested per surgeon 2.37 2 1–8
SNs found by pathologist 2.95 2 1–15
Cases with positive SN(s) 135
Cases with completion ALND 117
Positive nodes found at ALND 1.39 0 0–23
Nodes removed at ALND 15.7 15 5–40
Tumor histology
Invasive ductal cancer 333
Invasive lobular cancer 47
DCIS (treated with mastectomy and SLNB) 34
DCIS with microinvasion 25
Invasive cancer, ductal and lobular 10
Other (tubular, medullary, mucinous, papillary, Pagets, adenoid cystic, ADH) 29
SLNB, sentinel lymph node biopsy; SN, sentinel node; ALND, axillary lymph node dissection; DCIS, ductal carcinoma-in-situ; ADH,
atypical ductal hyperplasia.
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nical failures, lymphoscintigraphy confirmed failure
of the isotope to migrate to the axilla in two cases.
Mapping failures based on the method of injection
are listed in Table 2. Of 434 cases that received iso-
tope, mapping failures were infrequent (3.2% overall)
but occurred regardless of the method of isotope
injection. Mapping failures with dye injection (15%
overall) were much more common than for isotope
and occurred most frequently with peritumoral
injection (19.7%) despite the majority experience with
that method (239 of 462 cases). Pairwise comparisons
of injection techniques confirmed that peritumoral
injection had a higher mapping failure rate than pe-
ritumoral plus intradermal injection (P = .04 by
Fishers exact test for isotope and P = .007 by v2
analysis for dye). All other pairwise comparisons
among injection techniques for either dye or isotope
showed no significant differences.
Both dye and isotope were given in 418 cases,
including 380 with a positive lymphoscintigram. Of
these 380 cases, there were 6 cases in which a hot
node was not identified during surgery. In five cases,
only blue nodes were found, and in one case no
sentinel node was identified with radiotracer or blue
dye (Fig. 1). Therefore, the technical failure rate of
the SLNB procedure with a positive lymphoscinti-
gram was 1 (.3%) of 380, but it would have been 6
(1.6%) of 380 if dye had not been used.
One or more sentinel nodes containing metastasis
were found in 102 cases of the 380 with a positive
lymphoscintigram (Fig. 2). In 94 of 102 cases, the
metastatic sentinel node(s) were radioactive. In three
cases, one or more hot nodes were identified, but the
only sentinel nodes containing metastasis were blue
but not radioactive. The method of isotope injection
in all three of these cases was intradermal plus pe-
ritumoral (the most successful mapping technique for
isotope in this study). Therefore, the benefit of blue
dye cannot be attributed to using an inferior method
of isotope mapping. The blue dye injection was pe-
ritumoral in two cases and peritumoral plus intra-
dermal in one case. These three cases of axillary
metastasis would have been undetected if dye had not
been used, even in the setting of a positive lympho-
scintigram.
Because many of the patients with negative sentinel
nodes did not undergo completion axillary dissection
and because follow-up information is incomplete, the
absolute change in the false-negative rate for this
group of patients cannot be calculated. However, the
effect of blue dye on the false-negative rate can be
estimated by the following process. Assuming a false-
negative rate of 5%, if we identified 102 cases with a
positive sentinel node, then 5 additional cases with a
truly positive axilla were missed. If we had not used
dye, then we would have missed an additional 3 cases,
thus increasing the number of false-negative cases to
8 (7.5%) of 107—a 2.5% increase.
In 5 of 102 cases with axillary metastasis, the only
positive node found was neither hot nor blue. All five
of these cases had successful technical mapping pro-
cedures, with a hot and blue sentinel node identified.
However, none of these hot and blue sentinel nodes
contained metastasis. In three of the five cases, the
positive node was a node believed to be palpably
suspicious during the procedure. In the other two
cases, the positive node was an adjacent nonsentinel
node that was removed incidentally.
DISCUSSION
The optimal techniques for SLNB have been de-
bated,11 but there is considerable support for a dual
tracer technique.4,5,12–14 Several studies have found
that a dual tracer technique improves technical suc-
cess by 3% to 10%4,12–14 and reduces the false-nega-
tive rate by 2% to 6%.4,13,14 Despite these benefits,
controversy remains surrounding the routine use of
blue dye because of its potential toxicity. The most
widely used dye in lymphatic mapping for breast
cancer is isosulfan blue dye, which carries a risk of
acute inflammatory/hypersensitivity reactions,
including blue urticaria, hypotension, and life-
threatening anaphylaxis. These reactions have been
well documented.8,15–19 The frequency of any allergic
reaction in patients who receive isosulfan blue dye for
lymphatic mapping in breast cancer is reported as
1.6% to 2%,15,16 and the risk of anaphylaxis is re-
TABLE 2. Mapping failure and method of injection
Variable
No. of patients














a Hot node for isotope injection; blue node for dye injection.
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ported as .5% to .7%.15,16 One approach to reduce the
incidence of such reactions would be to use blue dye
selectively, i.e., as a backup technique, only in cases
in which lymphatic mapping with radiotracer fails.
When both blue dye and isotope are used routinely,
the value of preoperative lymphoscintigraphy is
questionable,20 although it is frequently performed.
We hypothesized that the blue dye, which carries
much of the risk of the procedure, could be avoided
in cases in which the lymphoscintigram demonstrates
a sentinel lymph node. This approach rests on the
assumption that lymphoscintigraphic success results
in technical operative success. Before adopting a
selective approach to the use of blue dye, we evalu-
ated the utility of blue dye in our patients who had a
positive lymphoscintigram. To our knowledge, the
benefit of blue dye has not been reported in this
subset of patients.
We found greater mapping success with isotope
than with dye, but there were mapping failures with
isotope regardless of the method of injection. There-
fore, blue dye should still provide some marginal
benefit for reducing the technical failure rate and for
reducing the false-negative rate, regardless of the
method of isotope injection. During this study, we
had very few patients with subareolar injection of
tracers. Reported mapping success rates with su-
bareolar injection are higher than those of the dye
injection techniques reported here.21 With increased
mapping success from subareolar injection of dye, the
benefits of complementary blue dye use may be even
further enhanced.
We assumed that our technical failure rate was 0%
when the lymphoscintigram confirmed uptake in an
axillary node(s). This assumption was wrong, because
we did not identify a hot node in every patient with a
positive lymphoscintigram. Possible reasons include
false-positive lymphoscintigrams and a diffusely hot
axilla. Wu et al.22 have also reported a small rate of
failure to harvest sentinel lymph nodes in patients
with successful preoperative lymphoscintigraphy. In
that study, a sentinel node was identified in 164 of 170
patients with a positive lymphoscintigram, thus con-
stituting a technical failure rate of 6 (3.5%) of 170. In
our series of patients, the routine use of blue dye im-
proved the technical success of lymphatic mapping by
1.3%, even when lymphatic mapping with radiotracer
seemed to be successful by lymphoscintigraphy.
A second benefit of using a dual tracer technique is
a reduction in the false-negative rate of SLNB. We
found that blue dye allowed identification of sentinel
node metastasis in three patients with positive lym-
phoscintigraphy. In these three patients, hot sentinel
nodes were harvested and found to be negative for
metastasis. With a selective use of blue dye, these
nodal metastases probably would have been missed,
and this would have increased the false-negative rate
FIG. 1. Effect of blue dye use on identification of sentinel nodes.
SLNB, sentinel lymph node biopsy.
FIG. 2. Effect of blue dye use on identification of positive sentinel
nodes (SN).
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by a few percentage points. DeRossis et al.14 showed
that the marginal benefit of blue dye diminished over
time in accordance with experience and the technical
success of the procedure, but even in their most recent
500 cases, blue dye still increased technical success
by 3% and reduced the false-negative rate by 2%.
DeRossis et al.14 acknowledge that these gains are
small but combine with other reasons that justify
continued use of a dual tracer mapping technique.
Use of the blue dye in addition to the isotope for
lymphatic mapping may also contribute to the tech-
nical ease of the procedure. The visual cues created by
blue-stained channels leading to the sentinel nodes or
the blue-green blush of a sentinel node that is
otherwise hidden within the axillary fat pad are
advantages unique to the blue dye. These subtle
advantages can increase the rapidity and facility with
which the sentinel lymph node is identified (whether
or not there is concomitant isotope uptake), but they
are not necessarily documented in the operative re-
cord.
Our findings demonstrate that a dual tracer lym-
phatic mapping method increases the technical suc-
cess and reduces the false-negative rate of sentinel
node biopsy in patients with a positive preoperative
lymphoscintigram; however, the magnitude of these
benefits was small (<5%). The question remains
whether these small gains are worth the potential
toxicity associated with the use of the blue dye, and
our findings prompt exploration of other options that
may still allow an optimal technique while cir-
cumventing the associated risks of administering blue
dye. Investigators at the MD Anderson Cancer
Center have reported on the effects of premedicating
with histamine blockers and corticosteroids before
isosulfan injection.23 Although this prophylaxis re-
duced the severity of allergic reactions, the wound
infection rate was greater in patients who received
corticosteroid prophylaxis. King et al.24 have re-
ported a trend toward fewer allergic reactions with
smaller volumes of injected dye, and they advocate
the use of the smallest volume of dye necessary.
The use of an alternative dye, methylene blue, has
been reported in a series of 112 patients.6 In this
retrospective review, intraparenchymal injection of 5
mL of 1% methylene blue dye was used in combina-
tion with radioisotope. The authors reported a
mapping success rate of 93% by dye and 96% overall,
with a dye/isotope concordance of 95%. Of patients
with positive sentinel nodes, 97% demonstrated dye
uptake. In a second study of methylene blue for
lymphatic mapping in breast cancer,7 a retrospective
comparison of 87 patients mapped with isosulfan
blue and 112 patients mapped with methylene blue
showed similar performance of the 2 dyes.
Although no toxicity was attributed to methylene
blue in these two series of patients, methylene blue
has been anecdotally associated with local inflam-
matory reactions leading to skin necrosis at the site of
injection. Stradling et al.25 reported skin lesions in 5
of 24 patients who received intradermal injection of
methylene blue dye for lymphatic mapping in breast
cancer. The skin lesions included a variety of local
inflammatory presentations, including erythematous
macular lesions, superficial ulcers, and necrotic
ulcerations. After injections were restricted to the
deep parenchyma, no further skin lesions were noted.
This local toxicity of methylene blue with superficial
injection concerns surgeons who perform subareolar
injection because of its potential effect on the nipple/
areolar complex. Some individuals have found that
dilution of methylene blue (2 mL of methylene blue
and 3 mL of saline) allows successful mapping while
avoiding this local toxicity (Pat Whitworth, MD,
personal communication, May 2004).
Although sentinel node biopsy in breast cancer has
been studied widely, continued optimization of tech-
niques will allow patients to benefit from a dual tracer
technique with minimal risks of blue dye adminis-
tration. We believe that the potential gains from use
of blue dye warrant its routine use, as well as con-
tinued research into strategies to reduce the toxicity
of blue dye.
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